Transplantation of allogeneic CD34⁺-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia

References

• Hansen JA, Clift RA, Thomas ED et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl 7 Med 1980;303:565–7.
   PubMed Web of Science ®Google Scholar
• Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397–404.
   PubMed Web of Science ®Google Scholar
• McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leu-kemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543–50.
   PubMed Web of Science ®Google Scholar
• Cornelissen jj, Carston M, Kollman C et al. Unrelated marrowtransplantation for adult patients with poor-risk acute lympho-blastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572–7.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion ofbone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000;95:3996–4003.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Weller E, Fisher DC et al. Comparable outcome withT-cell-depleted unrelated-donor versus related-donor allo-geneic bone marrow transplantation. Biol Blood Marrow Trans-plant 2002;8:601— 7.
   PubMed Web of Science ®Google Scholar
• Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002;43:2125–31.
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Risks of developing Epstein— Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998;91:3079–83.
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Platzbecker U, Theuser C et al. CD34±_ enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br y Haematol 2002;118:1095— 103.
   PubMed Web of Science ®Google Scholar
• Bunjes D. The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. Cytotherapy 2001;3:175–88.
   PubMed Web of Science ®Google Scholar
• Baron F, Seguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:351–9.
   PubMed Web of Science ®Google Scholar
• Porter DL, Collins RH Jr, Hardy C et al. Treatment of relapsedleukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214–21.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–5.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Peceny R, Steckel N et al. Outcome of transplantation of highly purified peripheral blood CD34± cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003;101:446— 53.
   PubMed Web of Science ®Google Scholar
• Ottinger HD, Muller CR, Goldmann SF et al. Second Germanconsensus on immunogenetic donor search for allotransplanta-tion of hematopoietic stem cells. Ann Hematol 2001;80:706–14.
   PubMed Web of Science ®Google Scholar
• Fritsch G, Scharner D, Froschl G et al. Selection of CD34-positive blood cells for allogeneic transplantation: approaches to optimize D34-cell recovery, purity, viability, and T-cell deple-tion. Onkologie 2000;23:449— 56.
   Google Scholar
• O'Donnell PV, Myers B, Edwards J et al. CD34 selection usingthree immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy 2001;3: 483— 8.
   Google Scholar
• Neumann F, Herold C, Hildebrandt B et al. Quantitative real-time reverse-transcription polymerase chain reaction for diag-nosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur 7 Haematol 2003;70: 1— 10.
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825— 8.
   Google Scholar
• Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroidrefractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001;28:47–9.
   PubMed Web of Science ®Google Scholar
• Ferra C, Rodriguez-Luaces M, Gallardo D et al. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:963 —8.
   PubMed Web of Science ®Google Scholar
• Urbano-Ispizua A, Rozman C, Martinez C et al. Rapid engraft-ment without significant graft-versus-host disease after allo-geneic transplantation of CD34± selected cells from peripheral blood. Blood 1997;89:3967–73.
   PubMed Web of Science ®Google Scholar
• Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic transplantation of selected CD34± cells from peripheral blood: experience of 62 cases using immunoadsorption or immuno-magnetic technique. Spanish group of allo-PBT. Bone Marrow Transplant 1998;22:519— 25.
   PubMedGoogle Scholar
• Roberts MM, Dyson P, Rawling C et al. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy 2003;5:534–41.
   PubMed Web of Science ®Google Scholar
• Goerner M, Weber-Nordt R, Hoepfner S et al. Addition of a lowfixed number of CD3± cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. Hematother Stem Cell Res 2003;12:309–20.
   PubMedGoogle Scholar
• Behringer D, Bertz H, Schmoor C et al. Quantitative lymphocytesubset reconstitution after allogeneic hematopoietic transplanta-tion from matched related donors with CD34± selected PBPC grafts unselected PBPC grafts or BM grafts. Bone Marrow Transplant 1999;24:295— 302.
   PubMed Web of Science ®Google Scholar
• Storek J, Storb R. T-cell reconstitution after stem-cell trans-plantation: by which organ. Lancet 2000;355:1843— 14.
   Google Scholar
• Fallen PR, McGreavey L, Madrigal JA et al. Factors affecting reconstitution of the T cell compartment in allogeneic haema-topoietic cell transplant recipients. Bone Marrow Transplant 2003;32:1001— 14.
   PubMed Web of Science ®Google Scholar
• Verfuerth S, Peggs K, Vyas P et al. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 2000;95:3990— 5.
   PubMed Web of Science ®Google Scholar
• Schwinger W, Urban C, Lackner H et al. Unrelated peripheral blood stem cell transplantation with `megadoses' of purified CD34± cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant 2000;25:513— 7.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Bachar-Lustig E, Li HW et al. The role of megadoseCD34± progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann NY Acad Sci 1999;872:336–48.
   PubMed Web of Science ®Google Scholar
• Rebello P, Cwynarski K, Varughese M et al. Pharmacokinetics ofCAMPATH-1H in BMT patients. Cytotherapy 2001;3:261–7.
   PubMed Web of Science ®Google Scholar
• Bunn D, Lea CK, Bevan DJ et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996;45:29— 32.
   PubMed Web of Science ®Google Scholar
• Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemruzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immu-notherapy and infectious complications. Blood 2003;102:404— 6.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Nakamura R, Read EJ et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:783–8.
   PubMed Web of Science ®Google Scholar
• Pihusch R, Holler E, Muhlbayer D et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:347— 54
   PubMed Web of Science ®Google Scholar
• Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011— 6.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002;100:397–405.
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Shpilberg 0, Drobyski WR et al. Donor leuko-cyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. 7 Clin Oncol 1997;15: 433–44.
   Google Scholar
• Chakrabarti S, Milligan DW, Pillay D et al. Reconstitution of theEpstein— Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839–42.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001;72:1460— 3.
   PubMedGoogle Scholar
• Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T celldepletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995;15:387–93.
   PubMed Web of Science ®Google Scholar
• Regn S, Raffegerst S, Chen X et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 2001;27:53— 64.
   PubMed Web of Science ®Google Scholar
• Einsele H, Bertz H, Beyer J et al. Infectious complications afterallogeneic stem cell transplantation: epidemiology and inter-ventional therapy strategies. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S175— 85.
   Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R et al. High incidence ofcytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357— 63.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Osman H, Collingham K, Milligan DW. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003;31:379–86.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H et al. Adenovirus infectionsfollowing allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002;100:1619–27.
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002;30:495–501.
   PubMed Web of Science ®Google Scholar
• Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment ofdonor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422 —9.
   PubMedGoogle Scholar
• Vasconcelos ZF, Diamond HR, Tabak DG, Barcinski MA, Bonomo A. Thl /Th2 lymphokine profile of T cells present in the blood of granulocyte-colony stimulating factor-treated stem-cell donors: up or down modulation. Blood 2001;97: 333–5.
   Google Scholar
• Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95: 2484— 90.
   Google Scholar
• Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4( ) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671–80.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8± T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002;8:625— 32.
   PubMed Web of Science ®Google Scholar
• Baron F, Frere P, Baudoux E et al. Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplan-tation with CD8-depleted peripheral blood stem cells: an update. Haematologica 2003;88:835— 7.
   PubMed Web of Science ®Google Scholar
• Baron F, Siquet J, Schaaf-Lafontaine N et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplan-tation. Haematologica 2002;87:78— 88.
   PubMed Web of Science ®Google Scholar
• Azuma E, Hirayama M, Yamamoto H, Komada Y. The role of donor age in naive T-cell recovery following allogeneic hematopoietic stem cell transplantation: the younger the better. Leuk Lymphoma 2002;43:735–9.
   PubMed Web of Science ®Google Scholar
• Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467–80.
   PubMed Web of Science ®Google Scholar
• Davison GM, Novitzky N, Kline A et al. Immune reconstitutionafter allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000;69:1341— 7.
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380–9.
   PubMed Web of Science ®Google Scholar
• Morecki S, Gelfand Y, Nagler A et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243–9.
   PubMed Web of Science ®Google Scholar
• Zorn E, Wang KS, Hochberg EP et al. Infusion of CD4 ± donorlymphocytes induces the expansion of CD8± donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002;8:2052— 60.
   PubMed Web of Science ®Google Scholar
• Anderson BE, McNiff J, Yan J et al. Memory CD4 ± T cells donot induce graft-versus-host disease. 7 Clin Invest 2003;112: 101— 8.
   PubMed Web of Science ®Google Scholar